Overview

A Trial of Vitamin B12 in Septic Shock

Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study will randomize 30 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to reduce vasopressor dose at 3 hours.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Hydroxocobalamin
Vitamin B 12
Vitamin B Complex
Vitamins